Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 19,039 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 19,039 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $7.45, for a total transaction of $141,840.55. Following the completion of the sale, the chief executive officer owned 1,035,466 shares of the company’s stock, valued at approximately $7,714,221.70. The trade was a 1.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vir Biotechnology Stock Up 27.7%

Shares of VIR opened at $9.49 on Wednesday. The stock’s 50-day moving average price is $6.80 and its 200 day moving average price is $5.99. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.29.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.Vir Biotechnology’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.76) EPS. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VIR. ARCH Venture Management LLC bought a new stake in Vir Biotechnology during the 2nd quarter worth approximately $65,100,000. GSK plc acquired a new position in Vir Biotechnology in the fourth quarter worth $51,562,000. Balyasny Asset Management L.P. bought a new stake in shares of Vir Biotechnology during the fourth quarter worth $8,252,000. State Street Corp increased its stake in shares of Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after buying an additional 988,262 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Vir Biotechnology by 129.2% in the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after buying an additional 787,212 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Needham & Company LLC raised their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target for the company in a research note on Tuesday. Barclays reiterated an “overweight” rating and issued a $30.00 price objective on shares of Vir Biotechnology in a research note on Tuesday. Morgan Stanley increased their target price on Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.